Alunbrig — Competitive Intelligence Brief

Alunbrig (brigatinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor [EPC]. Area: Oncology.

marketed Kinase Inhibitor [EPC] ALK tyrosine kinase receptor Oncology

Target snapshot

Alunbrig (brigatinib) — Takeda. Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Alunbrig TARGET	brigatinib	Takeda	marketed	Kinase Inhibitor [EPC]	ALK tyrosine kinase receptor	2017-01-01
Lorbrena	Lorlatinib	Pfizer	marketed	Kinase Inhibitor [EPC]	ALK tyrosine kinase receptor	2018-01-01
Lorbrena	lorlatinib	Pfizer	marketed	Kinase Inhibitor [EPC]	ALK tyrosine kinase receptor	2018-01-01
Tagrisso	osimertinib	AstraZeneca	marketed	Kinase Inhibitor [EPC]	ALK tyrosine kinase receptor	2015-01-01
Alecensa	alectinib	Hoffmann-La Roche	marketed	Kinase Inhibitor	ALK tyrosine kinase receptor	2015-01-01
Zykadia	ceritinib	Novartis	marketed	Kinase Inhibitor [EPC]	ALK tyrosine kinase receptor	2014-01-01
Wayrilz	RILZABRUTINIB	Genzyme Corp	marketed	Kinase Inhibitor [EPC]		2025-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2032-07-25 — Tagrisso · 9732058 · US
• 2032-07-25 — Tagrisso · 11524951 · US
• 2032-08-08 — Tagrisso · 8946235 · US
• 2035-01-02 — Tagrisso · 10183020 · US

Sponsor landscape (Kinase Inhibitor [EPC] class)

1. · 12 drugs in this class
2. Pfizer · 7 drugs in this class
3. Novartis · 3 drugs in this class
4. Bayer · 2 drugs in this class
5. Boehringer Ingelheim · 2 drugs in this class
6. AstraZeneca · 2 drugs in this class
7. Beigene Usa Inc · 1 drug in this class
8. BeiGene · 1 drug in this class
9. AbbVie · 1 drug in this class
10. Bristol · 1 drug in this class